Hyperparathyroidism, Secondary
32
0
0
25
Key Insights
Highlights
Success Rate
89% trial completion (above average)
Published Results
17 trials with published results (53%)
Clinical Risk Assessment
Based on trial outcomes
Low Risk
Score: 5/100
9.4%
3 terminated out of 32 trials
89.3%
+2.8% vs benchmark
50%
16 trials in Phase 3/4
68%
17 of 25 completed with results
Key Signals
Data Visualizations
Phase Distribution
Trial Status
Trial Success Rate
Benchmark: 86.5%
Based on 25 completed trials
Clinical Trials (32)
Safety and Efficacy of CTAP101 to Treat Secondary Hyperparathyroidism in Stage 3 or 4 CKD and Vitamin D Insufficiency
Safety and Efficacy of CTAP101 to Treat Secondary Hyperparathyroidism in Stage 3 or 4 CKD and Vitamin D Insufficiency
Impact of Parathyroidectomy on Vascular Calcification and Clinical Outcome in Hemodialysis Patients
Subtotal Parathyroidectomy or Total Parathyroidectomy With Autograft in Chronic Kidney Disease Patients Under Dialysis
Sodium Zirconium Cyclosilicate Lowers Hyperkalemia After Parathyroidectomy
Frequency of Hyperparathyroidism in Postmenopausal Osteoporosis and Its Treatment
Cholecalciferol Supplementation in Restless Leg Syndrome in Patients With Chronic Kidney Disease
Pediatric Chronic Kidney Disease Safety and Efficacy
Study to Evaluate Cinacalcet in Children With Chronic Kidney Disease
Safety & Tolerability of Cinacalcet in Pediatric Patients With Chronic Kidney Disease and Secondary Hyperparathyroidism
Study on the Use of Cinacalcet in Phosphocalcic Context.
Effect of CTAP101 Capsules on Ca/iPTH in Advanced Breast/Prostate Cancer Patients Treated With Denosumab/Zoledronic Acid
Efficacy and Safety of Etelcalcetide (AMG 416) in the Treatment of Secondary Hyperparathyroidism (SHPT) in Patients With Chronic Kidney Disease on Hemodialysis
Efficacy and Safety of Etelcalcetide (AMG 416) in the Treatment of Secondary Hyperparathyroidism (SHPT) in Patients With Chronic Kidney Disease (CKD) on Hemodialysis
Extension Study of Etelcalcetide in the Treatment of Secondary Hyperparathyroidism (SHPT) in Patients With Chronic Kidney Disease (CKD) on Hemodialysis
Study to Assess the Impact on Calcium Levels When Hemodialysis Patients With Secondary Hyperparathyroidism (SHPT) Switch From Cinacalcet to Etelcalcetide
Compare the Efficacy of Cinacalcet vs Traditional Vitamin D for Secondary Hyperparathyroidism (SHPT) Among Subjects Undergoing Hemodialysis
Safety, Tolerability and Pharmacokinetics of Etelcalcetide in Hemodialysis Patients With Secondary Hyperparathyroidism
Extension Study of Etelcalcetide for Treatment of Secondary Hyperparathyroidism in Patients With Chronic Kidney Disease on Hemodialysis
A Phase 2 Study of an Oral Vitamin D Compound (DP001) in Secondary Hyperparathyroidism in Patients on Hemodialysis